RT Journal Article
SR Electronic
T1 Alpha-synuclein seeds in olfactory mucosa of patients with isolated rapid-eye-movement sleep behaviour disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.04.20168328
DO 10.1101/2020.08.04.20168328
A1 Ambra Stefani
A1 Alex Iranzo
A1 Evi Holzknecht
A1 Daniela Perra
A1 Matilde Bongianni
A1 Carles Gaig
A1 Beatrice Heim
A1 Monica Serradell
A1 Luca Sacchetto
A1 Alicia Garrido
A1 Stefano Capaldi
A1 Almudena Sánchez-Gómez
A1 Michele Fiorini
A1 Joachim Schmutzhard
A1 Pietro Cocchiara
A1 Isabel Vilaseca
A1 Lorenzo Brozzetti
A1 Salvatore Monaco
A1 M. Jose Marti
A1 Klaus Seppi
A1 Eduardo Tolosa
A1 Joan Santamaria
A1 Birgit Högl
A1 Werner Poewe
A1 Gianluigi Zanusso
A1 for the SINBAR (Sleep Innsbruck Barcelona) group
YR 2020
UL http://medrxiv.org/content/early/2020/08/10/2020.08.04.20168328.abstract
AB Isolated REM sleep behaviour disorder is an early-stage α-synucleinopathy in most, if not all, affected subjects. Detection of pathological alpha-synuclein in peripheral tissues of isolated REM sleep behaviour disorder patients may identify those progressing to Parkinson’s disease, dementia with Lewy bodies or multiple system atrophy, with the ultimate goal of testing preventive therapies. Real-Time Quaking-Induced Conversion provided evidence of α-synuclein seeding activity in cerebrospinal fluid and olfactory mucosa of patients with α-synucleinopathies. Aim of this study was to explore Real-Time Quaking-Induced Conversion detection of α-synuclein aggregates in olfactory mucosa of large cohort of subjects with isolated REM sleep behavior disorder compared to Parkinson’s disease and controls.This prospective bicentric case-control study was performed between October 2017 and December 2018 at the Medical University of Innsbruck, Austria, and the Hospital Clinic de Barcelona, Spain. Olfactory mucosa samples obtained by nasal swab in 63 patients with isolated REM sleep behavior disorder, 31 matched Parkinson’s disease patients and 59 matched controls were analysed by α-synuclein Real-Time Quaking-Induced Conversion in a blinded fashion at the University of Verona, Italy. Median age of isolated REM sleep behavior disorder patients was 70 years, 85.7% were male. All participants were tested for smell, autonomic, cognitive and motor functions.Olfactory mucosa was α-synuclein Real-Time Quaking-Induced Conversion positive in 44.4% isolated REM sleep behavior disorder patients, 41.9% Parkinson’s disease and 10.2% controls. While the sensitivity for isolated REM sleep behavior disorder plus Parkinson’s disease versus controls was 40.9%, specificity was high (89.8%). Among isolated REM sleep behavior disorder patients with positive α-synuclein Real-Time Quaking-Induced Conversion, 78.6% had olfactory dysfunction as compared to 21.4% with negative α-synuclein Real-Time Quaking-Induced Conversion, p<0.001. The extent of olfactory dysfunction was more severe in positive than in negative α-synuclein Real-Time Quaking-Induced Conversion olfactory mucosa isolated REM sleep behavior disorder patients (p<0.001).We provide evidence that α-synuclein Real-Time Quaking-Induced Conversion assay enables the molecular detection of neuronal α-synuclein aggregates in olfactory mucosa of patients with isolated REM sleep behavior disorder and Parkinson’s disease. Although the overall sensitivity was moderate in this study, nasal swabbing is attractive as simple, non-invasive test, with a potential of use as screening test to identify subjects in the prodromal stages of α-synucleinopathies. Further studies are needed to enhance sensitivity, and better understand the temporal dynamics of α-synuclein seeding in the olfactory mucosa and spreading to other brain areas during the progression from isolated REM sleep behavior disorder to overt α-synucleinopathy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Ministero della Salute GR201302355724 to MB and GZ, Cariverona: Development and validation of a novel molecular assay for alpha-synuclein in patients with Parkinson's disease and other alpha-synucleinopathies to GZ and Brain Research Foundation Verona.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EK Nr: 1131/2018All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request to the corresponding author